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Abstract
Background
The clinical determinants of fibrosis progression in nonalcoholic fatty liver disease (NAFLD)
are still under definition.
Aim
To assess the clinical determinants of fibrosis progression rate (FPR) in NAFLD patients
with baseline and follow-up histological evaluation, with a special focus on the impact of
pharmacological therapy.
Methods
In an observational cohort of 118 Italian patients from tertiaryreferral centers, liver histology
was evaluated according to Kleiner. Independent predictors of FPR were selected by a
stepwise regression approach.
Results
Median follow-up was 36 months (IQR 24–77). Twenty-five patients (18%) showed some
amelioration, 63 (53%) had stability, 30 (25%) had progression of fibrosis. Patients with non-
alcoholic steatohepatitis (NASH) had similar demographic and anthropometric features, but
a higher prevalence of type 2 diabetes (T2D; p = 0.010), and use of renin-angiotensin axis
system (RAS) inhibitors (p = 0.005). Fibrosis progression was dependent of the length of fol-
low-up, and was associated with, but did not require, the presence of NASH (p<0.05). Both
fibrosis progression and faster FPR were independently associated with higher APRI score
at follow-up, absence of treatment with RAS inhibitors, and T2D diagnosis at baseline
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(p<0.05). There was a significant interaction between use of RAS inhibitors and T2D on
FPR (p = 0.002). RAS inhibitors were associated with slower FPR in patients with (p =
0.011), but not in those without (p = NS) T2D.
Conclusions
NASH is not required for fibrosis progression in NAFLD, whereas T2D seems to drive fibro-
genesis independently of hepatic inflammation. Use of RAS inhibitors may contrast fibrosis
progression especially in high-risk patients affected by T2D.
Introduction
Nonalcoholic fatty liver disease (NAFLD) is commonly held as the hepatic manifestation of
obesity and insulin resistance. Due to the worldwide epidemics of obesity and type 2 diabetes
(T2D), NAFLD is projected to become the leading cause of hepatocellular carcinoma and end-
stage liver disease within the next ten years[1]. Despite NAFLD affects nearly one third of the
population, progressive liver disease remains a relatively rare complication of this condition[1].
Cross-sectional studies have identified severity of overweight, T2D, muscle fitness, dietary fac-
tors, lack of use of lipid lowering drugs such as statins, and genetic predisposition as risk factors
for advanced disease [2–5]. However, the clinical determinants of progression of fibrosis, the
main determinant of liver-related outcomes and overall mortality[6,7], are still under defini-
tion. Indeed, data from prospective studies are still very limited[8,9]. Overall evidence suggests
that when steatosis is associated with hepatocellular damage and necroinflammation, that is
nonalcoholic steatohepatitis (NASH), higher AST/ALT ratio, and in the presence of hypergly-
cemia, fibrosis progression rate (FPR) is faster[8–10]. Yet, some individuals with simple steato-
sis have fast-progressing disease, especially when gain weight or develop T2D [9,11].
Furthermore, arterial hypertension has also been associated with faster FPR[12]. This suggests
that neuro-hormonal alterations associated with this condition, and in particular activation of
the renin-angiotensin system (RAS), directly favors steatosis, inflammation and fibrogenesis
via enhanced activation of hepatic stellate cells, whereas RAS inhibits contrast this process[13–
20]. In keeping, RAS inhibitors such as ACE-inhibitors or angiotensin receptor blockers have
been associated with improvement of liver damage[21], even if evidence is controversial[22].
Furthermore, in cross-sectional studies RAS inhibition protected from severe fibrosis in
patients with hypertension and NAFLD[23], and was associated with reduced liver stiffness in
patients with chronic kidney disease [24]
Aim of this study was therefore to assess the clinical determinants of FPR in an ethnically
homogeneous cohort of Italian patients with histological diagnosis of NAFLD, with a special
focus on the impact of pharmacological therapy.
Methods
Patients
In the study retrospective data collected from 118 consecutive patients from Italian ancestry
with clinical and histological diagnosis of NAFLD were prospectively evaluated. Patients were
followed-up at three tertiary referral centers in Italy (Milan, n = 67, 57%, Palermo, n = 32, 27%,
and Turin, n = 19, 16%), for whom a baseline and a follow-up liver biopsy and clinical data
were available between January 1992 and June 2015.
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In all patients other liver diseases were ruled out by standard assessment[2,25], and alcohol
intake (evaluated by a questionnaire) had to be lower than 30/20 g/day in males/females,
respectively. Patients with decompensated cirrhosis, hepatocellular carcinoma, and current use
of steatosis inducing drugs were also excluded.
In all subjects, first biopsy was performed for suspectedNASH in the presence of persis-
tently elevated liver enzymes, or a long history of NAFLD associated with severe insulin resis-
tance. Follow-up control biopsy was routinely offered to all compliant patients at five years, or
indicated when alterations in the clinical picture or imaging suggested progressive liver disease.
We also included patients randomized to iron depletion [26] or vitamin D supplementation
(http://www.webaisf.org/studi-e-ricerche/studi-in-corso.aspx) vs. lifestyle changes alone in
open label trials, as these treatments were not demonstrated to influence fibrosis progression.
Patients randomized to active arms in pharmacological studies, where the investigational prod-
uct was shown to improve liver histology, or who underwent bariatric surgery procedures
between the two biopsies (n = 13) were excluded.
The study was carried out in accordance with the principles of the Helsinki Declaration, and
with local and national laws. Approval was obtained from the hospital Internal ReviewBoards
and Ethics Committees of the Fondazione IRCCSCa’ Granda OspedaleMaggiore Policlinico
Milano, Azienda OspedalieraUniversitaria Citta´ della Salute e della Scienza Torino and
Azienda OspedalieraUniversitaria Policlinico Palermo and written informed consent was
obtained from all patients. Clinical and laboratory assessment is described in details in the Sup-
plementarymethods.
Histological analysis
Slides were coded and read by one expert pathologist at each center, who was unaware of
patients’ identity and history. A minimum 15mm-length of the biopsy specimen or the pres-
ence of at least 10 complete portal tracts was required[27]. Clinically significant steatosis was
defined as steatosis involving 5% of hepatocytes[28]. Diagnosis of NASH was based on the
presence of steatosis with both lobular necroinflammation and ballooning[28,29].Disease
activity and fibrosis stage were assessed according to the NAFLD activity score (NAS) and stag-
ing[28].We previously observed a good correlation for liver fibrosis assessment among the
centers involved in the study[30].
Statistical analysis
For descriptive statistics, continuous traits were summarized as means±SD. Highly skewed var-
iables, were summarized as medians and interquartile range, and log-transformed before analy-
sis. Categorical variables are shown as percentages. Baseline and follow-up clinical features of
patients were compared by chi-square and paired t-test, as required. Independent predictors of
fibrosis progression (increase in at least one stage) were determined by logistic regression, con-
sidering as independent variables those significant at univariate analysis. FPR was calculated by
taking the ratio between the difference of fibrosis stage and the time (months) between the
baseline and follow-up biopsy, and it was treated as a continuous variable. A multivariate
regression model with a stepwise regression procedure was set to identify the strongest predic-
tors of FPR, among all variables considered in the study (enlisted in supplementary material).
A significance level of 0.1 was defined to allow a variable into the model, and a significance
level of 0.25 was defined for a variable to stay into the model. A generalized linear model was
then fit to examine the independent predictors of FPR, excluding highly correlated variables to
avoid collinearity. In this final model, product terms between variables were evaluated to inves-
tigate the interaction between risk factors on FPR.
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Statistical analyses were carried out with JMP 12.0 (SAS Institute, Cary, NC) and SPSS 21.0
(IBM, Burbank, NJ). A two-sided P value<0.05 was considered statistically significant.
Results
Study cohort and clinical evolution at follow-up
The baseline clinical features of patients included in the study are shown in Table 1, left col-
umn. They were mostly middle-agedmen or post-menopausal women, overweight or obese,
with a high prevalence of metabolic alterations definingmetabolic syndrome and/or altered
liver enzymes (Table 1). Forty-two % had histological NASH.
At baseline liver biopsy, 16% of patients were on statins, 22% on RAS inhibitors (14 on
ACE-inhibitors and 12 on angiotensin receptor blockers). Indication for RAS inhibitors was
treatment of hypertension and/or micro-albuminuria in T2D in 14, and treatment of hyperten-
sion without T2D in 12. RAS inhibitors were not indicated for prevention of liver fibrosis pro-
gression in this cohort.
Table 1. Clinical features of 118 Italian patients with NAFLD, who underwent a follow-up liver biopsy.
Clinical features Baseline Follow-up p value
Sex, F 45 (38) 45 (38) 1.00
Age, years 47±12 51±11 <0.001
BMI, Kg/m2 30.6±6.6 29.0±7.2 0.006
T2D, yes 29 (25) 32 (27) 0.66
Glucose, mg/dl 98±25 102±25 0.13
Total cholesterol, mg/dl 194±44 189±43 0.066
HDL cholesterol, mg/dl 47±14 49±13 0.054
Triglycerides, mg/dl 111 {78–161} 111 {73–154} 0.078
Arterialhypertension, yes 38 (32) 54 (46) 0.033
ALT, IU/ml 50 {20–83} 40 {21–60} 0.002
AST, IU/ml 33 {23–51} 27 {21–36} 0.077
GGT, IU/ml 45 {28–80} 35 {19–63} 0.45
Ferritin (ng/mL) 234 {88–506} 138 {73–334} 0.012
Platelets (x10^9/L) 224 ± 71 224 ± 67 0.9
NASH, yes 49 (42) 47 (40) 0.79
APRI score 0.7 ± 1.7 0.4 ± 0.3 0.11
FIB4 score 1.3 ± 1.1 1.3 ± 0.9 0.82
NFS -1.7 ± 1.7 -1.6 ±1.6 0.79
RAS inhibitors, yes 26 (22) 36 (31) 0.14
Beta-blockers, yes 14 (12) 19 (16) 0.35
Calcium-antagonists, yes 12 (10) 11 (9) 0.81
Diuretics, yes 9 (8) 9 (8) 1.00
Metformin, yes 22 (19) 30 (26) 0.21
Statins, yes 16 (14) 28 (24) 0.045
Omega-3, yes 7 (6) 8 (7) 0.79
Vitamin E, yes 4 (3) 6 (5) 0.52
Iron depletion, yes 0 12 (10) <0.001
Length of follow-up, months 36 {24–77} -
Data are shown as mean±SD, frequency (%), median {IQR}, as required. BMI: body mass index; T2D: type 2 diabetes; RAS: renin angiotensin system. Less
than three patients (per drug class) were on glitazones, fibrates, and GLP-1 agonists/DPP-4 inhibitors.
doi:10.1371/journal.pone.0163069.t001
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Median follow-up was 36 months (IQR 24–77, range 7–196), for a total of 6,509 months. Clin-
ical features of patients at follow-up are shown in Table 1, right column. Patients lost on average
1.6 Kg/m2 of bodymass (p = 0.006), which was associated with reducedALT levels (p = 0.002).
The prevalence of arterial hypertension (p = 0.033), but not that of T2D, increased at follow-up.
At the end of the observation there was an increase in the prevalence of treatment with stat-
ins (p = 0.045). An additional 10% of patients had started RAS inhibitors (7 ACE-inhibitors
and 3 angiotensin receptor blockers; 2 with T2D, and 8 with hypertension without T2D;
p = NS). Twelve patients with baseline hyperferritinemia underwent iron depletion by phlebot-
omy during follow-up (p<0.001).
Fibrosis evolution during follow-up
The prevalence of histological NASH did not change significantly at follow-up (Table 1;
p = NS), although average NAS score decreased (median 4, IQR 2–5 at baseline vs. 3, IQR 2–5
at follow-up; p = 0.026). Non-invasive fibrosis scores did not significantly change at follow-up
(p = NS; Table 1).
Clinical features of patients stratified by the presence of baseline NASH are presented in
Table 2. Patients with NASH had a higher prevalence of T2D (p = 0.010), use of RAS inhibitors
(p = 0.005), and in the subgroup of patients for whom data were available, of prevalence of
PNPLA3 148M/M risk genotype (p = 0.023).
Evolution of liver fibrosis according to baseline stage is presented in Table 3, upper panel.
Of 118 patients, 25 (18%) showed some amelioration, 63 (53%) had stability, 30 (25%) had pro-
gression of fibrosis. Of note, 5 patients had progression to cirrhosis.Mean FPR was -0.002
±0.040. Evolution of fibrosis in patients stratified according to NASH at baseline is presented
in Table 3, middle and bottom panels, respectively. Fibrosis stage was more severe in patients
with NASH at baseline (p<0.001). FPR was non-significantly lower in patients with than in
those without baseline NASH (-0.011±0.054 vs. +0.004±0.033; p = 0.056), and it was not asso-
ciated with presence of necroinflammationwithout NASH (p>0.5). No single baseline histo-
logical feature of liver damage was able to predict FPR (S1 Table).
Clinical predictors of fibrosis progression
Baseline and follow-up clinical features of patients without baseline cirrhosis (n = 10) stratified
by progression status are presented in Table 4. Progression of fibrosis was associated with
length of follow-up (p = 0.027), lower HDL, absence of use of RAS inhibitors at baseline, AST
and ALT levels at baseline and follow-up, APRI score and NASH at follow-up (p<0.05). After
correction for duration of observation (Table 4), progression was associated with NASH at
baseline and follow-up, T2D at baseline and metformin use (likely a proxy of more severe
T2D) at follow-up, and AST and APRI score at follow-up (p<0.05). There was a non-signifi-
cant trend for a protective effect of use of RAS inhibitors. Among patients without NASH at
baseline (n = 69), 6 of 15 (43%) progressors developedNASH at follow-up, vs. 8/46 (15%) of
non-progressors (p = 0.044).
The association of the changes of clinical variables during follow-up with fibrosis progres-
sion is shown in S2 Table. None was associated with progression, even if at unadjusted analysis
development of new hypertension was associated with progression (8/30, 27% vs. 7/78, 9%;
p = 0.028). The noninvasive independent predictors of progression at multivariate logistic
regression analysis are shown in S3 Table. Duration of observation, lack of use of RAS inhibi-
tors, baseline NASH, T2D, and follow-up APRI score were associated with the likelihoodof
progression (p<0.05).
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Independent predictors of FPR
The independent predictors of FPR are shown in Table 5. Among variables selected by stepwise
regression, faster FPR was associated with higher APRI score at follow-up (p = 0.005), absence
of treatment with RAS inhibitors (p = 0.009), T2D diagnosis at baseline (p = 0.025). There was
a significant interaction between use of RAS inhibitors and T2D (p = 0.002).
The impact of RAS inhibitors use on FPR in patients stratified by the presence of T2D at
diagnosis is shown in Fig 1. RAS inhibitors were associated with slower FPR in patients with
(p = 0.011), but not in those without (p = 0.52) T2D.
Discussion
In this study, we evaluated the clinical determinants of FPR in a relatively large prospective
cohort of 118 Italian patients with histological NAFLD, with a special focus on the impact of
Table 2. Clinical features associated with presence of NASH at baseline evaluation.
Clinical features NASH (n = 49) Non-NASH (n = 69) p value
Sex, F 21 (43) 24 (35) 0.37
Age, years 48±12 47±12 0.49
BMI, Kg/m2 30.4±4.1 31.0±8.0 0.41
T2D, yes 18 (37) 11 (16) 0.010
Glucose, mg/dl 108±34 92±13 0.002
Total cholesterol, mg/dl 190±40 197±46 0.33
HDL cholesterol, mg/dl 47±15 48±15 0.67
Triglycerides, mg/dl 135±77 130±72 0.71
Arterialhypertension, yes 20 (41) 18 (26) 0.091
ALT, IU/ml 57 {41–95} 47 {24–77} 0.86
AST, IU/ml 37 {27–62} 31 {21–40} 0.60
GGT, IU/ml 54 {31–93} 42 {26–72} 0.45
Ferritin (ng/mL) 196 {51–408} 292 {75–523} 0.11
Platelets (x10^9/L) 237 ± 74 217 ± 70 0.16
NASH, yes 49 (42) 47 (40) 0.79
APRI score 0.5 ± 0.3 0.8 ± 2.2 0.37
FIB4 score 1.3 ± 0.8 1.3 ± 1.3 0.82
NFS -1.7 ± 1.5 -1.7 ±1.5 0.73
RAS inhibitors, yes 17 (35) 9 (13) 0.005
Beta-blockers, yes 7 (14) 7 (10) 0.49
Calcium-antagonists, yes 8 (16) 4 (6) 0.062
Diuretics, yes 4 (8) 5 (7) 0.85
Metformin, yes 16 (33) 6 (9) 0.001
Statins, yes 8 (16) 8 (12) 0.59
Omega-3, yes 4 (8) 3 (4) 0.39
Vitamin E, yes 4 (3) 6 (5) 0.52
Iron depletion, yes 3 (6) 9 (13) 0.22
PNPLA3 148 M/M 12/27 (44) 13/62 (21) 0.023
FPR, stage/month -0.01 ± 0.05 +0.004 ± 0.03 0.080
Follow-up, months 30 {7–144} 38 {9–196} 0.010
Data are shown as mean±SD, frequency (%), median {IQR}, as required. BMI: body mass index; T2D: type 2 diabetes; RAS: renin angiotensin system; FPR:
fibrosis progression rate.
doi:10.1371/journal.pone.0163069.t002
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pharmacological therapies. This is especially relevant for the clinical management because
fibrosis in the main prognostic indicator in patients with NAFLD [6,7]
In line with previous results[8], we observed that progression of fibrosis did not require the
presence of baseline NASH, despite NASH was related to more severe fibrosis at baseline and
associated with progression of fibrosis. However, follow-up liver biopsy was not systematically
performed in patients without baseline NASH. Therefore, an indication bias may have led to
selection of patients with worseningmetabolic status, liver enzymes, and noninvasive predic-
tors of liver damage. Indeed, in about half of the cases, progressors developedNASH at follow-
up. Notwithstanding, data suggest that preventive strategies and clinical trials should not only
focus on individuals with histological severe inflammation and hepatocellular ballooning. It is
therefore imperative to identify other risk factors and diseasemechanism contributing to dis-
ease evolution.
One may be represented by T2D and the severity of insulin resistance, which, in line with
data reported in a previous UK study evaluating a comparable number of patients[8], was iden-
tified as a predictor of fibrosis progression in the present cohort. There is ample literature on
the role of insulin resistance and hyperglycemia in the progression of NAFLD[3,31,32]. How-
ever, the mechanisms linkingmetabolic abnormalities with fibrosis progression independently
of NASH and inflammation, even in patients with normal liver enzymes[33], need further clar-
ification. Indeed, this may represent a different form of NAFLD progressing to hepatic
Table 3. Evolution of liver fibrosis by baseline disease stage in 118 Italian patients with NAFLD.
Overall
Follow-up Total =
Baseline Stage 0 Stage 1 Stage 2 Stage 3 Stage 4
Stage 0 21 (18) 8 (7) 4 (3) 3 (2) 0 36 (31)
Stage 1 6 (5) 21 (18) 6 (5) 2 (2) 0 35 (30)
Stage 2 1 (1) 6 (5) 9 (8) 2 (2) 2 (2) 20 (17)
Stage 3 1 (1) 5 (4) 3 (2) 5 (4) 3 (2) 17 (14)
Stage 4 0 1 (1) 2 (2) 0 7 (6) 10 (8)
Total = 29 (25) 41 (35) 24 (20) 12 (10) 12 (10) 118
NASH
Follow-up Total =
Baseline Stage 0 Stage 1 Stage 2 Stage 3 Stage 4
Stage 0 1 (2) 3 (6) 2 (4) 1 (2) 0 7 (14)
Stage 1 1 (2) 6 (12) 3 (6) 1 (2) 0 11 (22)
Stage 2 1 (2) 3 (6) 5 (10) 2 (2) 1 (2) 12 (25)
Stage 3 0 4 (8) 2 (4) 4 (8) 2 (4) 12 (25)
Stage 4 0 1 (2) 2 (4) 0 4 (8) 7 (14)
Total = 3 (6) 17 (35) 14 (29) 8 (16) 7 (14) 49
Non-NASH
Follow-up Total =
Baseline Stage 0 Stage 1 Stage 2 Stage 3 Stage 4
Stage 0 20 (18) 5 (7) 2 (3) 2 (2) 0 29 (42)
Stage 1 5 (5) 15 (18) 3 (5) 1 (2) 0 24 (35)
Stage 2 1 (1) 3 (5) 4 (8) 0 1 (2) 8 (12)
Stage 3 1 (1) 1 (4) 1 (2) 1 (4) 1 (2) 5 (7)
Stage 4 0 0 0 0 3 (6) 3 (4)
Total = 26 (38) 24 (35) 10 (14) 4 (6) 5 (7) 69
doi:10.1371/journal.pone.0163069.t003
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Table 4. Clinical features associated with fibrosis progression at baseline and follow-up evaluation in 108 patients with NAFLD without F4 fibrosis
at baseline.
Non-progressors (n = 78) Progressors (n = 30) p value p value*
Follow-up, months 36 {24–72} 60 {30–120} 0.027 1.00
BASELINE
Sex, F 27 (35) 11 (37) 0.83 0.28
Age, years 47±11 45±13 0.33 0.87
BMI, Kg/m2 30.7±8.0 29.9±8.4 0.55 0.75
T2D, yes 15 (19) 8 (27) 0.43 0.034
Glucose, mg/dl 98±27 98±21 0.98 0.15
Total cholesterol, mg/dl 200±47 188±33 0.16 0.12
HDL cholesterol, mg/dl 49±14 43±13 0.026 0.14
Triglycerides, mg/dl 129±70 137±86 0.75 0.88
Arterialhypertension, yes 25 (32) 6 (20) 0.24 0.40
ALT, IU/ml 47 {26–72} 72 {39–116} 0.024 0.17
AST, IU/ml 30 {23–39} 40 {26–55} 0.037 0.35
GGT, IU/ml 44 {25–80} 45 {32–65} 0.55 0.46
Ferritin (ng/mL) 161 {72–504} 335 {191–543} 0.12 0.35
Platelets (x10^9/L) 229 ± 51 215 ± 75 0.38 0.51
NASH, yes 27 (35) 15 (50) 0.18 0.037
APRI score 0.4 ± 0.3 1.2 ± 3.3 0.072 0.079
FIB4 score 1.1 ± 0.7 1.3 ± 1.3 0.18 0.060
NFS -1.8 ± 1.5 -1.9 ±1.8 0.92 0.53
RAS inhibitors, yes 20 (26) 2 (7) 0.028 0.059
Beta-blockers, yes 8 (10) 3 (10) 1.00 0.74
Calcium-antagonists, yes 7 (9) 0 0.19 0.99
Diuretics, yes 6 (8) 1 (3) 0.67 0.69
Metformin, yes 11 (14) 6 (20) 0.55 0.14
Statins, yes 10 (13) 3 (10) 1.00 0.98
Omega-3, yes 5 (6) 1 (3) 1.00 0.64
Vitamin E, yes 2 (3) 1 (3) 1.00 0.92
FOLLOW-UP
Age, years 52±11 51±11 0.81 0.67
BMI, Kg/m2 29.0±6.6 27.8±9.0 0.48 0.42
T2D, yes 17 (22) 9 (30) 0.45 0.094
Glucose, mg/dl 98±22 102±24 0.35 0.10
Total cholesterol, mg/dl 191±41 186±48 0.64 0.66
HDL cholesterol, mg/dl 49±12 46±13 0.26 0.37
Triglycerides, mg/dl 111±54 131±78 0.20 0.27
Arterialhypertension, yes 32 (41) 14 (47) 0.66 0.64
ALT, IU/ml 40 {20–52} 53 {29–82} 0.022 0.13
AST, IU/ml 27 {19–33} 35 {24–46} 0.006 0.014
GGT, IU/ml 28 {15–58} 42 {26–62} 0.36 0.29
Ferritin (ng/mL) 119 {70–296} 237 {90–427} 0.077 0.19
Platelets (x10^9/L) 220 ± 74 231 ± 67 0.49 0.40
NASH, yes 22 (28) 17 (57) 0.008 0.012
APRI score 0.3 ± 0.2 0.5 ± 0.4 0.018 0.008
FIB4 score 1.1 ± 0.7 1.5 ± 1.2 0.16 0.053
NFS -1.9 ± 1.4 -1.8 ±1.7 0.82 0.36
(Continued)
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complications by inflammation-independent pathways, for which specific noninvasive bio-
markers and therapeutic approaches should be developed.
Remarkably, fibrosis progression was associated with the length of the observation, being
more frequent in patients observed for an average 5-years period. This supports the
EASL-EASD-EASO guidelines that suggest to consider re-biopsy after this timeframe[29].We
also identified the absolute value of APRI score, not reported in a previous cohort[8], as the
most reliable predictor of fibrosis progression. These results need however replication.
An important novel aspect that could be addressed in the present database, but could not be
evaluated in a previous meta-analysis and in a recent study [8,9], was the impact of therapies
on FPR. A major finding was that patients in treatment with RAS inhibitors had slower FPR,
and lower likelihoodof fibrosis progression. Furthermore, use of RAS inhibitors resulted inde-
pendently associated with lack of fibrosis progression also at logistic regression analysis consid-
ering variables associated at univariate analysis, providing an independent confirmation of this
association by an alternative approach. This is in line with accumulating evidence indicating
that angiotensin is involved in hepatic stellate cells activation, while RAS inhibitors contrast
fibrogenesis in experimentalmodels[13–20], and their use was associated with protection from
fibrosis in cross-sectional studies in patients with NAFLD and kidney disease[23,24]. Interest-
ingly, the protective effect of RAS inhibitors was particularly evident in patients with T2D, but
not in patients with arterial hypertension in general. This would suggest that activation of RAS
represents a specific feature driving both kidney [34] and hepatic fibrogenesis in T2D.
Table 4. (Continued)
Non-progressors (n = 78) Progressors (n = 30) p value p value*
RAS inhibitors, yes 24 (31) 6 (20) 0.34 0.25
Beta-blockers, yes 24 (14) 5 (17) 0.74 0.50
Calcium-antagonists, yes 6 (8) 0 0.18 0.99
Diuretics, yes 6 (8) 1 (3) 0.67 0.69
Metformin, yes 15 (19) 10 (33) 0.14 0.043
Statins, yes 10 (13) 3 (10) 0.60 0.24
Omega-3, yes 2 (3) 3 (10) 0.13 0.54
Vitamin E, yes 2 (3) 1 (3) 1.00 0.37
Iron depletion, yes 11 (14) 1 (3) 0.17 0.14
Data are shown as mean±SD, frequency (%), median {IQR}, as required.
* p value adjusted for duration of observation at logistic regression analysis.
BMI: body mass index; T2D: type 2 diabetes; RAS: renin angiotensin system.
doi:10.1371/journal.pone.0163069.t004
Table 5. Independent predictors of FPR in 118 Italian patients with NAFLD (including 10 with F4 fibro-
sis at baseline).
FPR predictor Estimate±SE p value
APRI at f-up, per unit +0.04±0.01 0.005
RAS inhibitors at baseline or f-up -0.012±0.004 0.009
T2D at baseline, yes +0.010±0.004 0.025
Beta-blockers at baseline or f-up -0.008±0.005 0.14
BMI variation, Kg/m2 +0.001±0.001 0.14
Hypertension at baseline or f-up +0.006±0.005 0.24
SE: standard error; F-up: follow-up.
doi:10.1371/journal.pone.0163069.t005
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Noteworthy, activation of the neuro-vegetative system is associated with induction of RAS acti-
vation, and the two have a synergic role in the pathogenesis of arterial hypertension and kidney
dysfunction in overweight individuals[35].More widespread use of RAS inhibitors in patients
with baseline NASH may have contributed to the slow FPR observed in this subgroup despite
severe histological activity. On the other hand, we could not detect any significant effect of stat-
ins [2,36], or iron depletion [37] on FPR.
Limitations of this study include that the sample size did not allow to test the effect of spe-
cific therapeutic molecules on FPR, and to test for a dose-response effect. Furthermore, find-
ings may not be extended to other ethnic groups and populations with different genetic and
lifestyle risk factors. This study does not report results of a randomized trial, therefore the asso-
ciation of therapeutic approaches with liver disease evolution should be considered as hypothe-
sis generating, and not as a proof of efficacy. In addition, treatment of T2D has recently
evolved, but in the present cohort only a few patients were taking oral hypoglycemic drugs
other than metformin. Larger collaborative studies are needed to better characterize the impact
of new as well as “old” pharmacological treatments on the progression of liver disease in
NAFLD.
Fig 1. Impact of RAS inhibitors on FPR in patients stratified by the presence of T2D at baseline.
doi:10.1371/journal.pone.0163069.g001
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In conclusion, our data confirm that NASH is not required for fibrosis progression in
NAFLD, whereas T2D seems to drive fibrogenesis independently of hepatic inflammation.
Most importantly, we could show for the first time in a prospective evaluation of retrospec-
tively collected data by two independent approaches that use of RAS inhibitors may contrast
fibrosis progression especially in high-risk patients affected by T2D. These findings further
reinforce the indication of use RAS inhibitors to treat arterial hypertension or initial kidney
disease in T2D patients in the presence of NAFLD.
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